Where Will Viking Therapeutics Stock Be in 10 Years?

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech company, went public almost 11 years ago. Since then, the drugmaker's stock has performed well, while it has made significant clinical progress. Viking Therapeutics' leading candidate is now undergoing pivotal studies. The company is approaching what could be the most important period in its history as it awaits clinical trial data, which should be released within the next 18 months. For investors focused on the long game, it's important to gauge how the drugmaker's prospects might look beyond that. That said, let's discuss where Viking Therapeutics might be in 10 years.Image source: Getty Images.Viking Therapeutics is developing medicines for weight management, with its leading candidate, VK2735, being a dual GLP-1/GIP agonist. VK2735 is undergoing a pair of 78-week phase 3 studies, the second of which recently completed enrollment. The medicine's results in mid-stage clinical trials were strong, and it will also need to demonstrate competitive efficacy to carve out a niche in the growing weight-loss market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool